The arrival of GLP-1 medications like Ozempic® and Wegovy® has been nothing short of revolutionary for weight loss and diabetes management. These drugs, which include active ingredients like ...

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

The average weight increase after 52 weeks for Wegovy patients was 2 pounds, whereas Zepbound patients gained 11 pounds. Eli ...

The average participant getting a 12-mg weekly injection lost 71 pounds in 68 weeks.  "This is beyond what we see with any ...

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

For the last installment of the America in Focus project this year, we spoke with 14 Americans from all walks of life who are ...

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...

U.S. drug maker Eli Lilly & Co. is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by ...

Judges allow consolidation of vision loss lawsuits filed against Novo Nordisk and Eli Lilly over diabetes and weight loss ...

Claudia Oshry is back on weight loss drugs now that she’s done breast-feeding her baby boy. The Girl With No Job creator took ...

Real-world data show semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are linked with lower risk of major ...

Despite the widespread popularity of new weight-loss medications, research suggests a non-drug alternative is significantly ...